Long-term outcome after infliximab for refractory ulcerative colitis

Journal of Crohn's and Colitis

Volumn 2, Issue 3, 2008, Pages 219-225

  Ferrante, Marc ^a   Vermeire, Séverine ^a   Fidder, Herma ^a   Schnitzler, Fabian ^a   Noman, Maja ^a   Van Assche, Gert ^a   De Hertogh, Gert ^a   Hoffman, Ilse ^a   D'Hoore, Andre ^a   Van Steen, Kristel ^b   Geboes, Karel ^a   Penninckx, Freddy ^a   Rutgeerts, Paul ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Anti TNF; Colectomy; Inflammatory bowel disease; Infliximab; Outcome; Predictor; Ulcerative colitis

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB;

ADULT; AGED; ARTICLE; COLON RESECTION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG WITHDRAWAL; EVALUATION; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; INFECTION; INFLAMMATION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MORTALITY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REFRACTORY ANEMIA; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 48949099032     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2008.03.004     Document Type: Article

References (14)

1. Hanauer S.B. Medical therapy for ulcerative colitis 2004. Gastroenterology 126 6 (2004) 1582-1592
2. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 23 (8-12-2005) 2462-2476
3. Ferrante M., Vermeire S., Katsanos K.H., et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 13 2 (2007) 123-128
4. Mcgovern D.P.B., Ahmad T., van Heel D., and Jewell D.P. A genetic panel strongly predicts the need for colectomy in ulcerative colitis. Gastroenterology 126 4 (2004) A68
5. Silverberg M.S., Satsangi J., Ahmad T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19 Suppl A (2005) 5-36
6. Schroeder K.W., Tremaine W.J., and Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317 26 (24-12-1987) 1625-1629
7. Beaugerie L., Massot N., Carbonnel F., Cattan S., Gendre J.P., and Cosnes J. Impact of cessation of smoking on the course of ulcerative colitis. Am J Gastroenterol 96 7 (2001) 2113-2116
8. Selvasekar C.R., Cima R.R., Larson D.W., et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 204 5 (2007) 956-962
9. Fidder H., Schnitzler F., Ferrante M., et al. Long-term safety of infliximab in the treatment of inflammatory bowel disease: a single center cohort study. J Crohn's Colitis Suppl 1 1 (2007) 3
10. Jakobovits S.L., Jewell D.P., and Travis S.P.L. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford From 2000 to 2006. Aliment Pharmacol Ther 25 9 (1-5-2007) 1055-1060
11. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 9317 (4-5-2002) 1541-1549
12. Parsi M.A., Achkar J.P., Richardson S., et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 123 3 (2002) 707-713
13. Vermeire S., Louis E., Carbonez A., et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 97 9 (2002) 2357-2363
14. Travis S. Review article: saving the colon in severe colitis - the case for medical therapy. Aliment Pharmacol Ther 24 (2006) 68-73